XML 74 R11.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings Per Share
 9 Months Ended
Sep. 30, 2025
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per ShareAbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.
The following table summarizes the impact of the two-class method:
Three months ended
September 30,		Nine months ended
September 30,
(in millions, except per share data)2025202420252024
Basic EPS
Net earnings attributable to AbbVie Inc.$186 $1,561 $2,410 $4,300 
Earnings allocated to participating securities10 10 30 30 
Earnings available to common shareholders$176 $1,551 $2,380 $4,270 
Weighted-average basic shares outstanding1,769 1,769 1,769 1,769 
Basic earnings per share attributable to AbbVie Inc.$0.10 $0.88 $1.35 $2.41 
Diluted EPS
Net earnings attributable to AbbVie Inc.$186 $1,561 $2,410 $4,300 
Earnings allocated to participating securities10 10 30 30 
Earnings available to common shareholders$176 $1,551 $2,380 $4,270 
Weighted-average shares of common stock outstanding1,769 1,769 1,769 1,769 
Effect of dilutive securities3 3 3 3 
Weighted-average diluted shares outstanding1,772 1,772 1,772 1,772 
Diluted earnings per share attributable to AbbVie Inc.$0.10 $0.88 $1.34 $2.41 
Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.